Browsing Tag
Beckley Psytech
3 posts
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
atai Beckley emerges as new global leader after atai Life Sciences and Beckley Psytech complete strategic merger in mental-health biotech
Find out how atai Life Sciences and Beckley Psytech’s merger to form atai Beckley is reshaping psychedelic biotech and transforming depression treatment.
Atai Life Sciences stock jumps 15% after Beckley Psytech trial update deepens investor interest in BPL-003
Atai Life Sciences stock surged 15% after positive BPL-003 trial data with Beckley Psytech. Investors eye Phase 3 momentum and merger milestones.